SIGY · Sigyn Therapeutics, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“The Company had an accumulated deficit of $17,379,978 at September 30, 2025, had a working capital deficit of $3,903,920 at September 30, 2025, had net losses of $578,503 and $2,698,254, and $1,196,923 and $2,817,394 for the three and nine months ended September 30, 2025 and 2024, respectively, and net cash used in operating activities of $646,208 and $582,218 for the nine months ended September 30, 2025 and 2024, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Nov 14, 2025
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $9929 | — | — | — | — | — | $143.32K | $28.35K | $38.43K | $29.21K | $43.15K | |
| $3637 | — | — | — | — | — | $35.67K | $9712 | $21.43K | $9930 | $25.25K | |
| $6292 | — | — | — | — | — | $107.66K | $18.64K | $17K | $19.28K | $17.9K | |
| — | — | — | — | — | — | 75.12% | 65.74% | 44.24% | 66% | 41.49% | |
| $140.1K | $773.28K | $798.17K | $657.66K | $734.01K | $419.36K | — | — | — | — | — | |
| $1.7M | $1.74M | $1.66M | $1.49M | $1.27M | $496.37K | $613.78K | $862.41K | $1.05M | $833.55K | $399.88K | |
| — | — | $2100 | $3600 | $16.21K | $10.95K | $0 | — | — | — | — | |
| $1.88M | $2.52M | $2.46M | $2.15M | $2.01M | $916.43K | $625.62K | $1.02M | $2.05M | $2.27M | $405.45K | |
| -$1.88M | -$2.52M | -$2.46M | -$2.15M | -$2.01M | -$916.43K | -$517.96K | -$1M | -$2.03M | -$2.25M | -$387.54K | |
| — | — | — | — | — | — | -361.39% | -3544.18% | -5277.41% | -7714.35% | -898.05% | |
| $307.21K | — | — | — | — | $343.16K | $55.2K | $352.84K | $790.84K | -$441.18K | — | |
| -$1.34M | -$820.97K | -$1.69M | -$782.55K | -$996.4K | -$343.16K | -$2.8M | -$1.3M | -$1.82M | $441.18K | — | |
| -$3.22M | -$3.34M | -$4.15M | -$2.93M | -$3M | -$1.26M | -$3.31M | -$2.3M | -$3.84M | -$2.69M | -$387.54K | |
| — | — | — | — | — | — | — | $800 | $800 | — | — | |
| -$3.22M | -$3.34M | -$4.15M | -$2.93M | -$3M | -$1.26M | -$3.07M | -$2.62M | -$4.25M | -$2.69M | -$387.54K | |
| — | — | — | — | — | — | -2145.3% | -9243.24% | -11061.21% | -9224.88% | -898.05% | |
| USD/shares | -$1.93 | -$2.51 | -$3.77 | -$3.13 | -$3.20 | — | — | — | — | — | — |
| USD/shares | -$1.93 | -$2.51 | -$3.77 | -$3.13 | — | — | — | — | — | — | — |
| shares | — | 1.33M | 1.1M | 934.92K | 909.91K | 183.78K | 2.03M | 1.63M | 1.18M | 774.82K | 698.8K |
| shares | — | 1.33M | 1.1M | 934.92K | 909.91K | 183.78K | 2.03M | 1.63M | 1.18M | 774.82K | 698.8K |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Long-term debt, including current maturities | 2025-09-30 | USD 3,549,793 | 10-Q filed 2025-11-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Short-term borrowings | 2025-09-30 | USD 304,637 | 10-Q filed 2025-11-14 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.